Advancing Inflammatory Bowel Disease Management With Precision Medicine and Emerging Data
Overview
This text module covers the current prevalence and impact of inflammatory bowel disease (IBD), how to integrate treat to target into one’s practice, and data on several emerging TL1A inhibitors and the promise they pose in transforming the IBD treatment landscape.
Nurse Practitioners/Nurses: 0.75 Nursing contact hour
Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit
Physicians: maximum of 0.75 AMA PRA Category 1 Credit™
Disclosures
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Jordan E. Axelrad, MD, MPH, FACG: consultant/advisor/speaker: AbbVie, Abviax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, Vedanta; researcher: BioFire Diagnostics, Genentech, Janssen.
The planners and content peer reviewers from Clinical Care Options, LLC and the American Gastroenterological Association (AGA) do not have any relevant financial relationships to disclose.
Learning objectives
Upon completion of this activity, participants should be able to:
- Detail available and emerging biomarkers and diagnostics informing treatment decisions in IBD
- Incorporate available biomarkers appropriately into clinical practice based on guideline recommendations and expert consensus
- Evaluate evidence for the utility of TL1A blockade in IBD treatment
Key dates
- Released date:
- May 08, 2025
- Expiration date:
- May 07, 2026
Sponsor
Provided by Clinical Care Options, LLC in partnership with the American Gastroenterological Association (AGA)
Supporter acknowldegement
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Agenda
All times are Eastern.
Session Heading 1: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Session Heading 2: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Course Faculty and Disclosures
Faculty
.jpg?sv=2018-03-28&sr=c&sig=OBlWtJHfYtJCkJVPsRD5O1AsWZtqBsIBWPgt%2BPtaEFk%3D&st=2025-10-19T14%3A08%3A45Z&se=2025-10-19T18%3A13%3A45Z&sp=r)
Jordan Axelrad, MD, MPH, FACG
Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health Associate Professor of Medicine NYU Grossman School of Medicine New York, New York